To evaluate second-line osimertinib resistance, Le et al. [45] retrospectively surveyed The University of Texas MD Anderson Lung Cancer Moon Shot GEMINI database for advanced NSCLC patients who had been treated with osimertinib and the Moffitt electronic health record, Clinical Genomic Action Committee database, from Moffitt Cancer Center and Research Institute (MCC) for NSCLC patients with EGFR T790M mutations. Here, EGFR is linked to non-small cell lung carcinoma.